• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮下注射阿扑吗啡:药代动力学与代谢

Subcutaneously administered apomorphine: pharmacokinetics and metabolism.

作者信息

LeWitt Peter A

机构信息

Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA.

出版信息

Neurology. 2004 Mar 23;62(6 Suppl 4):S8-11. doi: 10.1212/wnl.62.6_suppl_4.s8.

DOI:10.1212/wnl.62.6_suppl_4.s8
PMID:15037665
Abstract

Apomorphine is a non-narcotic morphine derivative that acts as a potent dopaminergic agonist. Its high first-pass hepatic metabolism prevents effectiveness by the oral route; instead, subcutaneous injection is the usual route, and intranasal, sublingual, rectal, and iontophoretic transdermal delivery has been investigated for the treatment of Parkinson's disease (PD). The rate of uptake after subcutaneous injection is influenced by factors such as location, temperature, depth of injection, and body fat. Studies have shown the latency of onset to clinical effect after s.c. injection ranged from 7.3 to 14 minutes. Cerebrospinal fluid T(max)lags behind plasma T(max) by 10 to 20 minutes. Considerable intersubject variability is found with pharmacokinetic variables; in some studies there are five- to tenfold differences in C(max)and area-under-the-concentration-time-curve seen in PD patients. Apomorphine metabolism occurs through several enzymatic pathways, including N-demethylation, sulfation, glucuronidation, and catechol-O-methyltransferase as well as by nonenzymatic oxidation. The complexities of apomorphine uptake, distribution, and clearance probably contribute to its variability of clinical actions.

摘要

阿扑吗啡是一种非麻醉性吗啡衍生物,作为一种强效多巴胺能激动剂发挥作用。其较高的首过肝脏代谢使其口服无效;相反,皮下注射是常用途径,鼻内、舌下、直肠和离子导入透皮给药已被研究用于治疗帕金森病(PD)。皮下注射后的吸收速率受注射部位、温度、注射深度和体脂等因素影响。研究表明,皮下注射后临床起效的潜伏期为7.3至14分钟。脑脊液T(max)比血浆T(max)滞后10至20分钟。在药代动力学变量方面存在相当大的个体间差异;在一些研究中,帕金森病患者的C(max)和浓度-时间曲线下面积存在5至10倍的差异。阿扑吗啡通过多种酶促途径代谢,包括N-去甲基化、硫酸化、葡萄糖醛酸化和儿茶酚-O-甲基转移酶以及非酶促氧化。阿扑吗啡吸收、分布和清除的复杂性可能导致其临床作用的变异性。

相似文献

1
Subcutaneously administered apomorphine: pharmacokinetics and metabolism.皮下注射阿扑吗啡:药代动力学与代谢
Neurology. 2004 Mar 23;62(6 Suppl 4):S8-11. doi: 10.1212/wnl.62.6_suppl_4.s8.
2
Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?舌下含服阿扑吗啡:帕金森病治疗的一种新药理学方法?
J Neural Transm Suppl. 1995;45:157-61.
3
Pharmacokinetics of apomorphine in Parkinson's disease.阿扑吗啡在帕金森病中的药代动力学
J Neural Transm Suppl. 1995;45:137-41.
4
Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.帕金森病患者经鼻内和皮下应用后阿扑吗啡的药代动力学
Eur J Drug Metab Pharmacokinet. 1995 Jan-Mar;20(1):27-33. doi: 10.1007/BF03192285.
5
Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.阿扑吗啡在帕金森病治疗中的有效给药:临床医生和帕金森病护士的实际考量
Clin Neuropharmacol. 2015 May-Jun;38(3):89-103. doi: 10.1097/WNF.0000000000000082.
6
Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease.逐步静脉输注阿扑吗啡以确定帕金森病患者的治疗窗。
Clin Neuropharmacol. 1998 May-Jun;21(3):152-8.
7
Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.皮下注射阿扑吗啡:关于其在帕金森病中应用的循证综述
Drugs Aging. 2004;21(11):687-709. doi: 10.2165/00002512-200421110-00001.
8
Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.健康受试者和帕金森病患者舌下膜阿扑吗啡和皮下注射阿扑吗啡的群体药代动力学分析。
Clin Transl Sci. 2021 Jul;14(4):1464-1475. doi: 10.1111/cts.13008. Epub 2021 May 2.
9
Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient.阿扑吗啡的离子电渗疗法:从体外模型到帕金森病患者
Adv Drug Deliv Rev. 2002 Nov 1;54 Suppl 1:S57-75. doi: 10.1016/s0169-409x(02)00119-9.
10
Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.帕金森病患者中阿扑吗啡的药代动力学-药效学关系。
Clin Pharmacokinet. 1999 Sep;37(3):257-71. doi: 10.2165/00003088-199937030-00004.

引用本文的文献

1
Effectiveness of Continuous Dopaminergic Therapies in Parkinson's Disease: A Review of L-DOPA Pharmacokinetics/Pharmacodynamics.帕金森病中连续多巴胺能疗法的效果:L-多巴药代动力学/药效学的综述。
J Parkinsons Dis. 2024;14(5):925-939. doi: 10.3233/JPD-230372.
2
Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease.药物治疗的新选择:帕金森病“关”期症状按需治疗药物的比较。
J Parkinsons Dis. 2023;13(4):441-451. doi: 10.3233/JPD-230055.
3
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.
G 蛋白偶联受体在神经退行性疾病和精神障碍中的作用。
Signal Transduct Target Ther. 2023 May 3;8(1):177. doi: 10.1038/s41392-023-01427-2.
4
Closing the loop for patients with Parkinson disease: where are we?为帕金森病患者闭环:我们在哪里?
Nat Rev Neurol. 2022 Aug;18(8):497-507. doi: 10.1038/s41582-022-00674-1. Epub 2022 Jun 9.
5
A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson's disease.基于深共晶溶剂的阿扑吗啡皮下储库系统用于帕金森病的治疗。
Proc Natl Acad Sci U S A. 2022 Mar 1;119(9). doi: 10.1073/pnas.2110450119.
6
Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease.用于治疗帕金森病的阿扑吗啡给药系统的挑战与趋势
Asian J Pharm Sci. 2018 Nov;13(6):507-517. doi: 10.1016/j.ajps.2017.11.004. Epub 2017 Dec 6.
7
Apomorphine: The Initial Indian Experience in Relation to Response Tests and Pumps.阿扑吗啡:印度在反应测试和泵方面的初步经验
Ann Indian Acad Neurol. 2020 Jan-Feb;23(1):20-24. doi: 10.4103/aian.AIAN_428_19. Epub 2019 Dec 19.
8
Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.阿扑吗啡治疗帕金森病:现有和新型制剂的疗效和安全性。
CNS Drugs. 2019 Sep;33(9):905-918. doi: 10.1007/s40263-019-00661-z.
9
, a Forgotten Potential Therapy for Parkinson's Disease?,一种被遗忘的帕金森病潜在疗法?
Mov Disord Clin Pract. 2015 Oct 6;3(1):19-26. doi: 10.1002/mdc3.12242. eCollection 2016 Jan-Feb.
10
Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.阿扑吗啡在帕金森病中的应用的药理学研究进展:临床相关性。
Clin Drug Investig. 2018 Apr;38(4):287-312. doi: 10.1007/s40261-018-0619-3.